Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Caffeine in 2019-nCoV: The Co-Evolutionary Protecting Agent

*Corresponding Author:

Copyright: © 2022  . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 
To read the full article Peer-reviewed Article PDF image

Abstract

The current outbreak of COVID‐19 caused by 2019‐nCoV has already taken away plethora of human lives. There is an urgent need for cost effective, available, safe, and effective medicine for fighting this virus. As on date, there is no specific medication available for COVID-19. The bitter taste receptor -TAS2R family (present in human airway smooth muscle) is an important player in host defence mechanisms. Considering the caffeine role as bitter agonists to stimulate the TAS2Rs and to activate host defence mechanisms and to suppress the cytokine storms due to its anti-inflammatory action, caffeine can play as an agent for support therapy in the control of SARS-COV-2. Studies demonstrate that caffeine apart from its role as a central nervous system stimulant has proven the ability as an antiviral agent by its role in inhibiting viral protein synthesis. This article is an approach to attract the attention of caffeine researchers to highlight onto the possibilities and suggest the population with beneficial and accessible remedies.

Keywords

Top